MARKET

SRRK

SRRK

Scholar Rock Holding
NASDAQ
47.62
+3.17
+7.13%
After Hours: 47.59 -0.03 -0.06% 19:58 02/06 EST
OPEN
45.77
PREV CLOSE
44.45
HIGH
48.00
LOW
44.73
VOLUME
1.20M
TURNOVER
--
52 WEEK HIGH
49.82
52 WEEK LOW
22.71
MARKET CAP
4.86B
P/E (TTM)
-15.1194
1D
5D
1M
3M
1Y
5Y
1D
Is Scholar Rock (SRRK) Pricing Reflect Its Strong Multi Year Share Performance Gains
Simply Wall St · 1d ago
BUZZ-Novo Nordisk, obesity firms drop on report of Hims Wegovy pill copy launch
Reuters · 2d ago
Scholar Rock Insider Sales Coincide With Key Apitegromab Launch Decisions
Simply Wall St · 3d ago
A Look At Scholar Rock (SRRK) Valuation After A Strong 3 Month Share Price Return
Simply Wall St · 4d ago
Weekly Report: what happened at SRRK last week (0126-0130)?
Weekly Report · 5d ago
Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026
NASDAQ · 6d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Scholar Rock Holding (SRRK) and Standard BioTools (LAB)
TipRanks · 01/30 17:02
Scholar Rock Holding Price Target Raised to $58.00/Share From $44.00 by HC Wainwright & Co.
Dow Jones · 01/26 12:42
More
About SRRK
Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.

Webull offers Scholar Rock Holding Corp stock information, including NASDAQ: SRRK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRRK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRRK stock methods without spending real money on the virtual paper trading platform.